Cas:765-10-6 1-Tetradecyne manufacturer & supplier

We serve Chemical Name:1-Tetradecyne CAS:765-10-6 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

1-Tetradecyne

Chemical Name:1-Tetradecyne
CAS.NO:765-10-6
Synonyms:n-Dodecyl-acetylen;MFCD00015076;1-C14H26;1-tetradecine;tetradec-1-in;Tetradecyne;EINECS 212-139-6;1-Tetradecyne;tetradec-1-yne
Molecular Formula:C14H26
Molecular Weight:194.356
HS Code:

Physical and Chemical Properties:
Melting point:N/A
Boiling point:251.7±3.0 °C at 760 mmHg
Density:0.8±0.1 g/cm3
Index of Refraction:1.445
PSA:
Exact Mass:194.203445
LogP:6.84

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like n-Dodecyl-acetylen chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,tetradec-1-yne physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1-Tetradecyne Use and application,Tetradecyne technical grade,usp/ep/jp grade.


Related News: A number of factors influenced the decision by the U.S. Centers for Disease Control and Prevention, including the COVID-19 pandemic, too few facilities to quarantine dogs safely and three recent incidents where rabies-infected dogs were brought into the country, CNN reported. 1-Tetradecyne manufacturer A number of factors influenced the decision by the U.S. Centers for Disease Control and Prevention, including the COVID-19 pandemic, too few facilities to quarantine dogs safely and three recent incidents where rabies-infected dogs were brought into the country, CNN reported. 1-Tetradecyne supplier The program will run alongside our ongoing Phase 3 INSPIRE Trial, and is expected to continue until commercial launch in such countries. 1-Tetradecyne vendor The GLOW trial doesn’t yet have the answer to that question, but Tendler pointed to encouraging early evidence from the regimen’s phase 2 trial, dubbed CAPTIVATE. Among eight patients who progressed after stopping the fixed-duration combo, six responded to subsequent Imbruvica monotherapy, while the other two didn’t have a response report, according to data presented at the recent American Society of Clinical Oncology annual meeting. 1-Tetradecyne factory The South Korean government is banning entry to all foreign nationals who visited China’s Hubei province in the past 14 days.